Amgen stock (US0311621009): Biotech leader navigates patent cliffs and pipeline momentum

Amgen Inc., a biotech powerhouse, continues to drive innovation in oncology and rare diseases amid key patent expirations. US investors track its robust dividend and growth prospects in a competitive sector.

Amgen Inc. remains a cornerstone for US investors seeking exposure to biotechnology, with its portfolio spanning blockbuster drugs and emerging therapies. The company reported steady progress in its pipeline, including recent data on obesity treatments, positioning it strongly in high-growth areas. Shares have shown resilience, trading around recent levels amid broader market dynamics.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe, global
• Key revenue drivers: Oncology, cardiovascular, inflammation drugs
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen Inc. develops and markets human therapeutics based on cellular and molecular biology, focusing on serious illnesses like cancer, heart disease, and bone disorders. Its business model relies on a mix of mature blockbusters and innovative pipeline candidates, with manufacturing and global distribution capabilities supporting sales in over 100 countries. The company invests heavily in R&D, spending billions annually to advance biologics and biosimilars.

Key to Amgen's strategy is its emphasis on high-barrier-to-entry products, leveraging proprietary technologies like Prolia for osteoporosis and Repatha for cholesterol reduction. This approach has sustained profitability, with a track record of dividend growth appealing to income-focused US investors listed on Nasdaq.

Main revenue and product drivers for Amgen Inc.

Amgen's top revenue generator is Enbrel, used for rheumatoid arthritis, though facing biosimilar competition. Oncology drugs like Kyprolis and Blincyto contribute significantly, while Prolia and Xgeva dominate bone health. In 2024 full-year results published in February 2025, total revenue reached $32.8 billion, up 18% from prior year, driven by volume growth in rare disease therapies, according to Amgen 10-K as of 02/05/2025.

Emerging drivers include MariTide, an obesity candidate showing promising Phase 2 data, and Tarpeyo for kidney disease. These aim to offset patent cliffs on older drugs, with US market exposure providing stability amid economic cycles.

Industry trends and competitive position

The biotech sector faces patent expirations and pricing pressures, but Amgen's diversified portfolio and $8 billion cash position as of Q4 2024 filings bolster its stance against rivals like Eli Lilly and Regeneron. Trends in GLP-1 agonists for obesity favor Amgen's experimental assets, with US approvals critical for revenue acceleration.

Amgen holds a strong position in monoclonal antibodies, commanding premium pricing in oncology where it captures significant US Medicare market share.

Why Amgen Inc. matters for US investors

Listed on Nasdaq, Amgen offers US investors direct access to biotech innovation with substantial exposure to the world's largest pharma market. Its products treat prevalent conditions like cancer and osteoporosis, aligning with aging demographics and driving consistent demand.

Dividend yield around 3%, backed by 12 years of increases, provides income stability rare in growth-oriented biotech, making it relevant for diversified portfolios tracking S&P 500 health care indices.

Conclusion

Amgen Inc. exemplifies biotech resilience, balancing mature revenues with pipeline promise amid industry headwinds. US investors value its Nasdaq listing, dividend reliability, and US-centric growth drivers. Ongoing developments in obesity and oncology warrant monitoring as the company navigates competition and innovation cycles.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.